Home > Publications database > Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. > print

001     137640
005     20240229105113.0
024 7 _ |a 10.1016/j.ccell.2018.08.004
|2 doi
024 7 _ |a pmid:30205044
|2 pmid
024 7 _ |a 1535-6108
|2 ISSN
024 7 _ |a 1878-3686
|2 ISSN
024 7 _ |a altmetric:48069530
|2 altmetric
037 _ _ |a DKFZ-2018-01520
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Archer, Tenley C
|b 0
245 _ _ |a Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups.
260 _ _ |a Cambridge, Mass.
|c 2018
|b Cell Press
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1565682984_20521
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a There is a pressing need to identify therapeutic targets in tumors with low mutation rates such as the malignant pediatric brain tumor medulloblastoma. To address this challenge, we quantitatively profiled global proteomes and phospho-proteomes of 45 medulloblastoma samples. Integrated analyses revealed that tumors with similar RNA expression vary extensively at the post-transcriptional and post-translational levels. We identified distinct pathways associated with two subsets of SHH tumors, and found post-translational modifications of MYC that are associated with poor outcomes in group 3 tumors. We found kinases associated with subtypes and showed that inhibiting PRKDC sensitizes MYC-driven cells to radiation. Our study shows that proteomics enables a more comprehensive, functional readout, providing a foundation for future therapeutic strategies.
536 _ _ |a 319H - Addenda (POF3-319H)
|0 G:(DE-HGF)POF3-319H
|c POF3-319H
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
700 1 _ |a Ehrenberger, Tobias
|b 1
700 1 _ |a Mundt, Filip
|b 2
700 1 _ |a Gold, Maxwell P
|b 3
700 1 _ |a Krug, Karsten
|b 4
700 1 _ |a Mah, Clarence K
|b 5
700 1 _ |a Mahoney, Elizabeth L
|b 6
700 1 _ |a Daniel, Colin J
|b 7
700 1 _ |a LeNail, Alexander
|b 8
700 1 _ |a Ramamoorthy, Divya
|b 9
700 1 _ |a Mertins, Philipp
|b 10
700 1 _ |a Mani, D. R.
|b 11
700 1 _ |a Zhang, Hailei
|b 12
700 1 _ |a Gillette, Michael A
|b 13
700 1 _ |a Clauser, Karl
|b 14
700 1 _ |a Noble, Michael
|b 15
700 1 _ |a Tang, Lauren C
|b 16
700 1 _ |a Pierre-François, Jessica
|b 17
700 1 _ |a Silterra, Jacob
|b 18
700 1 _ |a Jensen, James
|b 19
700 1 _ |a Tamayo, Pablo
|b 20
700 1 _ |a Korshunov, Andrey
|0 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
|b 21
|u dkfz
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 22
|u dkfz
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 23
|u dkfz
700 1 _ |a Northcott, Paul A
|0 P:(DE-HGF)0
|b 24
700 1 _ |a Sears, Rosalie C
|b 25
700 1 _ |a Lipton, Jonathan O
|b 26
700 1 _ |a Carr, Steven A
|b 27
700 1 _ |a Mesirov, Jill P
|b 28
700 1 _ |a Pomeroy, Scott L
|b 29
700 1 _ |a Fraenkel, Ernest
|b 30
773 _ _ |a 10.1016/j.ccell.2018.08.004
|g Vol. 34, no. 3, p. 396 - 410.e8
|0 PERI:(DE-600)2074034-7
|n 3
|p 396 - 410.e8
|t Cancer cell
|v 34
|y 2018
|x 1535-6108
909 C O |o oai:inrepo02.dkfz.de:137640
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 21
|6 P:(DE-He78)8d9c904a6cea14d4c99c78ba46e41f93
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 23
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 24
|6 P:(DE-HGF)0
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-319H
|2 G:(DE-HGF)POF3-300
|v Addenda
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2018
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b CANCER CELL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 20
|0 StatID:(DE-HGF)9920
|2 StatID
|b CANCER CELL : 2015
920 1 _ |0 I:(DE-He78)G380-20160331
|k G380
|l KKE Neuropathologie
|x 0
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 1
920 1 _ |0 I:(DE-He78)L101-20160331
|k L101
|l DKTK Heidelberg
|x 2
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)G380-20160331
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)L101-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21